Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study
Luca Gianni(IRCCS Ospedale San Raffaele), Giuseppe Viale(University of Milan)
Cited by 382
Related Papers
Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer
|Breast Cancer Research|2017|129
Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours
|British Journal of Cancer|2014|103